About the Authors
- Karen Nieto
-
* E-mail: k.nieto@dkfz.de
Affiliation Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany
- Margit Weghofer
-
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Peter Sehr
-
Affiliation Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany
- Mirko Ritter
-
Current address: Roche Diagnostics GmbH, Penzberg, Germany
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Sebastian Sedlmeier
-
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Balasubramanyam Karanam
-
Affiliation Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America
- Hanna Seitz
-
Affiliation Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany
- Martin Müller
-
Affiliation Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany
- Markus Kellner
-
Current address: GE Healthcare, Fast Trak Services, Munich, Germany
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Markus Hörer
-
Current address: Rentschler Biotechnologie GmbH, Laupheim, Germany
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Uwe Michaelis
-
Affiliation MediGene AG, Planegg/Martinsried, Germany
- Richard B. S. Roden
-
Affiliation Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America
- Lutz Gissmann
-
Affiliation Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany
- Jürgen A. Kleinschmidt
-
Affiliation Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany
Competing Interests
The authors have read the journal’s policy and have the following conflicts: MW, MR, SS, MK, MH and UM are or were employees of MediGene AG when the study was performed. MR, SS, MK, MH and UM hold stocks or stock options of MediGene AG. The corresponding author had full access to all the data and had the final editorial rights of the manuscript. MR and MH are inventors to a patent application with the application number PCT/EP2011/004528 entitled “Cross-protective HPV L2 vaccine based on AAVLPs” filed by MediGene AG. RBSR is a co-inventor on L2 patents licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MH JAK MM LG. Performed the experiments: KN PS SS BK RBSR MK MR. Analyzed the data: KN PS MW. Contributed reagents/materials/analysis tools: HS MR MK. Wrote the paper: KN JAK MM MW LG. Organizational support: UM.